NCT05667597View on ClinicalTrials.gov

Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

NAActive, not recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
SARS CoV 2 InfectionCOVID-19
Interventions
DIAGNOSTIC_TEST

Humoral immunity

determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).

Trial Locations (1)

1050

Sciensano, Brussels

All Listed Sponsors
collaborator

Université Libre de Bruxelles

OTHER

collaborator

Institute of Tropical Medicine

OTHER_GOV

collaborator

Mensura EDPB

UNKNOWN

collaborator

Erasme University Hospital

OTHER

lead

Maria Goossens

OTHER_GOV